- Home
- MANE vs RCUS Comparison
MANE vs RCUS Comparison
Compare MANE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | RCUS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MANE | RCUS |
|---|---|---|
| Price | $102.80 | $30.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $83.33 | $31.90 |
| AVG Volume (30 Days) | 796.4K | ★ 1.2M |
| Earning Date | 03-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.26 | $10.40 |
| 52 Week High | $131.24 | $31.74 |
Technical Indicators
Market Signals| Indicator | MANE | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 59.71 |
| Support Level | $91.62 | $25.94 |
| Resistance Level | $116.86 | $31.41 |
| Average True Range (ATR) | 5.77 | 1.10 |
| MACD | -0.99 | 0.19 |
| Stochastic Oscillator | 34.34 | 78.79 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.